Based on a mouse model that is homozygous for D409V, developed by Sardi and colleagues [5], Sanofi has made significant investments in using venglustat, a substrate reduction therapy (SRT) capable of crossing the blood–brain barrier (BBB) in phase I and phase II clinical trials for patients with GBA1-PD [6,7]. This evidence concerns the gene GBA1 and Parkinson disease.